Canis ISSN: 2398-2942

Insulin glargine

Contributor(s): Rhett Marshell, Prof Jacquie Rand, Dr Linda Fleeman

Introduction

Name

  • Insulin glargine.

Class of drug

  • Insulin analogue.

Description

Molecular formula

  • C267H404N72O78S6.

Molecular weight

  • 6063.

Physical properties

  • Clear, sterile, aqueous solution containing 100 unit/mL insulin glargine.

Storage requirements

  • Should be stored in refrigerator before use, but may be kept for 28 days at room temperature away from direct light and heat (<30°C) when contained within an insulin dosing pen that is in use.
  • Once vials are in use, the manufacturer recommends discarding unused insulin after 28 days. However, problems have not been reported with continued use beyond 28 days.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • To treat diabetes mellitus in cats.
  • To treat diabetic dogs Diabetes mellitus Diabetes mellitus that do not respond to lente or NPH insulin preparations.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

With other drugs

  • There are no known interactions of glargine with other drugs, but in general the following drugs may increase or decrease the effect of insulin:
  • Drugs which potentiate the effect of insulin include:
  • Drugs which reduce the glucose lowering effects of insulin include:
    • Corticosteroids.
    • Dobutamine Dobutamine.
    • Adrenalin.
    • Thiazide diuretics.
    • Thyroid hormones.

With diagnostic tests

  • Not known.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed Papers

  • Recent references from VetMed Resource and PubMed.
  • Sparkes A, Cannon M, Church D, Fleeman L M et al (2016) ISFM consensus guidelines on the practical management of diabetes mellitus in cats. J Feline Med Surg 17 , 235-250.
  • Thompson A L, Lathan P, Fleeman L M (2015) Update on insulin treatment for dogs and cats: insulin dosing pens and more. Veterinary Medicine: Research and Reports 6 , 129-142https://www.dovepress.com/update-on-insulin-treatment-for-dogs-and-cats-insulin-dosing-pens-and--peer-reviewed-article-VMRR.
  • Hess R S, Drobatz K J (2013) Glargine insulin for treatment of naturally occurring diabetes melllitus in dogs. JAVMA 243 (8), 1154-1161PubMed.
  • Marshall R D, Rand J S, Gunew M N, Menrath V H (2013) Intramuscular glargine with or without concurrent subcutaneous administration for treatment of feline diabetic ketoacidosis. JVECC 23 (3), 286-290PubMed.
  • Gilor C, Graves T K (2010) Synthetic insulin analogs and their use in dogs and cats. Vet Clin North Am Small Anim Pract 40 , 297-307PubMed.
  • Marshall R D, Rand J S, Morton J M (2009) Treatment of newly diagnosed diabetic cats with glargine insulin improves glycemic control and results in higher probability of remission than protamine zinc and lente insulins. J Feline Med Surg 11 (8), 683-691PubMed.
  • Marshall R D, Rand J S, Morton J M (2008) Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats. J Feline Med Surg 10 , 488-494.
  • Marshall R D, Rand J S, Morton J M (2008) Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. J Vet Pharmacol Ther 31 , 205-212PubMed.

ADDED